Cannabinoid-focused biopharmaceutical company C3 Pharmaceuticals, Inc. announced Wednesday that it has executed a tailored share subscription agreement with GEM Global Yield LLC SCS and is planning on listing on the Canadian Securities Exchange.
The California company said it has a commitment of CAD$135 million ($99.3 million) from GGY. The money will expand manufacturing operations and introduce Idrasil, the company’s cannabis-based tablet, to the U.S. and international markets, according to C3.
The tablet is aimed at helping patients manage a variety of conditions, such as chronic pain, ADD, Alzheimer’s, cancer, sleep disorders, mental health issues and withdrawal from opioid addiction, while remaining sober and lucid.
“Idrasil is expected to be a highly disruptive medical advancement in recent pharmaceutical history,” CEO Steele Smith III said in Wednesday’s press release. “This is why there have been legal and…
